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ABSTRACT
BACKGROUND: Ramadan, the ninth month of the Islamic lunar calendar, is the
holy month of fasting for adolescent and adult Muslims. Observance of Ramadan is
considered obligatory for every healthy adult Muslim. During this time, Muslims
refrain from eating, drinking, smoking, and administering oral or parenteral medica-
tions from sunrise to sunset daily for 28 to 30 days.
CASE SUMMARY: We evaluated the need for changes in basal insulin regimen
in 5 patients (4 males and 1 female; age range, 15-19 years) with type 1 diabetes
mellitus (T1DM) who fasted during Ramadan. The patients were receiving insulin
pump therapy with regular human insulin and maintained weekly visits with their
endocrinologist at The Chronic Care Center (Beirut, Lebanon). They were instructed
to break the fast after any episode of hypoglycemia (finger stick glucose <70 mg/dL)
or severe hyperglycemia (finger stick glucose ::0-300 mg/dL or any hyperglycemia as-
sociated with presence of urine ketone bodies on urinary dipstick). Blood glucose
concentrations did not change significantly with fasting. Finger stick blood glucose
taken at 4-hour intervals decreased in the afternoon (at 4 PM) and increased in the
evening and morning (l0 PM and 8 AM, respectively) during this month in 4 of
5 patients, while no significant change in circadian rhythm of finger stick blood glu-
cose was observed in 1 patient. Based on the investigators' findings, the basal insulin
requirement decreased by 5.5% to 25.0% (4 patients) or did not change (l patient)
during the fast. Changes in regimens, based on collaboration between the endocri-
nologist and diabetes educational nurse, were determined by blood glucose self-
monitoring done at 4-hour intervals during the fasting period, pre-Suhur (predawn
breakfast), and::o-2 hours after Iftar (evening fast-breaking meal). No cases of keto-
acidosis or severe hypoglycemia were reported.
CONCLUSION: These 5 adolescent and adult patients with T1DM who were using
an insulin pump were able to fast during Ramadan without incidences of severe
hypoglycemia or ketoacidosis by using close blood glucose self-monitoring and weekly
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follow-up with their endocrine team, which consisted of an endocrinologist, a regis-
tered nutritionist, and a diabetes educational nurse. (Curr Ther Res Clin Exp. 2009;70:29-
34) © 2009 Excerpta Medica Inc.
KEY WORDS: type 1 diabetes, Ramadan fasting, insulin pump therapy, blood
glucose concentration, diabetes control.
INTRODUCTION
Ramadan takes place in the ninth lunar month of the Islamic year and lasts for 28 to
30 days. Fasting during Ramadan is 1 of the 5 pillars of Islam. 1 Muslims strictly re-
frain from eating, drinking, smoking, and receiving oral or parenteral medications
from sunrise until sunset, which can vary from 11 to 19 hours depending on geo-
graphic location and the time of the year that Ramadan occurs. 2 Two meals per day
are eaten during this month, 1 before sunrise and the other after sunset. 3 Normally,
the fast is not associated with harmful effects. However, in patients with diabetes mel-
litus (DM), it could lead to serious complications.4 For this reason, patients with type 1
DM (T1DM) are exempt from fasting; however, some wish to adhere to the fast. s
According to a large multicenter survey, ~79% of patients with type 2 DM (T2DM)
and 43% with T1DM were able to fast ~15 days during Ramadan. 6
There remains a lack of consensus regarding the management of DM during Ra-
madan. Physicians may advise their fasting patients to adhere to a regimen that in-
cludes close self-monitoring of blood glucose and observation by a physician. Accord-
ing to Kassem et al,7 an appropriate insulin regimen for fasting patients with T1DM
consists of ~85% of their initial total insulin dose, which comprises 70% basal insulin
and 30% rapid insulin administered in equal amounts at sunrise and sunset.
With the widespread use of insulin pump treatment in T1DM, patients whose
disease is well controlled during prolonged fasting might desire to fast during Rama-
dan. However, fasting is known to accelerate lipolysis and ketosis and to increase
glucagon concentrations, which puts patients with T1DM at risk for hypoglycemia.s
The aim of this small case series was to investigate basal insulin adjustment in
patients using insulin pump therapy who wished to fast during Ramadan.
CASE SUMMARY
Five patients (4 males and 1 female; age range, 15-19 years) with T1DM who at-
tended The Chronic Care Center in Beirut, Lebanon, a center that specializes in treat-
ing children and adolescents with DM, were evaluated. The patients, who were
treated with an insulin pump using regular human insulin, chose to fast during the
month of Ramadan despite medical advice. All patients gave oral informed consent to
participate in the study. An institutional review board waiver was obtained because
patients wished to fast during Ramadan under weekly physician supervision. During
each visit, the physician reviewed their daily blood glucose levels recorded in diaries
as well as the total insulin requirements per day. Doses of basal insulin therapy were
adjusted weekly based on patients' glucose control or if any hyperglycemic or hypo-
glycemic events had occurred. The patients fasted for ~ 12 hours a day for 4 weeks.
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The amount of basal insulin prefast was adjusted weekly by the investigators based on
patients' daily finger stick blood glucose control and the occurrence of any adverse
events in each patient individually during the fast.
The patients were instructed to measure their blood glucose concentration every
4 hours during the fasting period and ::0-2 hours after Iftar (evening fast-breaking meal)
using finger stick testing. They were instructed to follow a reasonable traditional family
Ramadan diet, except for avoiding sweets, excessive intake of carbohydrates, and exces-
sive eating after breaking the fast. The patients were instructed to base their food con-
sumption on carbohydrate counting. They were also instructed to measure ketone con-
centrations using a urine dipstick with every blood glucose concentration ::0-300 mg/dL
and to immediately break the fast in case of symptomatic hypoglycemia (defined as
finger stick blood glucose level <70 mg/dL with symptoms of tremor, altered mental
status and/or confusion, perspiration, or palpitations). Patients observing the fast under-
went weekly physician visits. Basal insulin requirement was initially decreased by 20%
from the prefast basal insulin regimen and further adjustment was made by the endo-
crinologist based on the daily blood glucose self-monitoring by each patient.
During the fast, the basal insulin requirement decreased (4 patients) or did not change
(1 patient) by 5.5% to 25.0% based on each patient's blood glucose concentration.
Based on clinical observation and collaboration between the endocrinologist and
diabetes educational nurse, the bolus doses of insulin remained the same at sunrise and
sunset. The percentage change in basal insulin dosing during Ramadan ranged from
0% to -25.0%. The glycosylated hemoglobin (HbA1c) concentration ranged from
6.5% to 7.9% before Ramadan. At the end of Ramadan, the HbA1c concentration
ranged from 6.8% to 7.9%, which was not clinically different compared with baseline
in any patient. Blood glucose concentrations did not significantly change with fasting
(Table). Finger stick blood glucose concentrations taken at 4-hour intervals decreased
in the afternoon (at 4 PM), ranging between 72 and 90 mg/dL, and increased in the eve-
ning ::0-2 hours postprandial after Iftar (evening fast-breaking meal)-at 10 PM-
ranging between 170 and 273 mg/dL and in early morning (at 8 AM), ranging be-
tween 188 and 248 mg/dL in 4 of the 5 patients. There was no significant change in
circadian rhythm of finger stick blood glucose in 1 patient whose blood glucose con-
centrations ranged between 90 and 160 mg/dL.
None of the patients developed ketoacidosis or severe symptomatic daytime or
nocturnal hypoglycemia that required IV glucose or 1M glucagon administration.
DISCUSSION
In patients receiving insulin pump therapy, the basal insulin regimen during the fast
either remained unchanged or decreased by 5.5% to 25.0% of the total prefast regi-
men. Our finding that HbA1c concentration at the end of Ramadan was not clinically
different from baseline is consistent with results from previously published studies in
patients with T1DM and T2DMJ,9,lO One study7 recommended that patients with
T1DM who wished to fast be switched to long-acting insulin such as ultralente. The
authors indicated that the total insulin dose should consist of ~85% of the patient's
initial insulin dose and should be comprised of ~70% ultralente and 30% rapid insu-
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Table. Demographic and clinical characteristics of 5 patients with type 1 diabetes mellitus at baseline, during Ramadan, and at
the end of the Ramadan fast.
Basal Insulin Mean Basal Change in Basal
Duration of Dose Insulin Dose Adjusted Insulin Dosing During HbA1c HbA1c Post-
Patient Age, Diabetes, Pre-Ramadan, During Ramadan, Ramadan Fast, Pre-Ramadan, Ramadan,
No. y y U U % % %
1 15 11 32.6 32.6 0 6.9 7.4
2 16 4 41.3 37.4 -9.4 6.9 7.8
3 19 5 29.0 22.0 -24.1 6.5 6.8
4 17 4 21.7 20.5 -5.5 7.9 7.9
5 17 5 56.0 42.0 -25.0 6.9 7.0
HbA1c = glycosylated hemoglobin.
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lin, divided equally between Suhur and Iftar. Another studylO recommended that an
appropriate insulin regimen consist of ~70% of the patient's initial total insulin dose
comprised 60% insulin glargine and 40% rapid insulin such as lispro or aspart di-
vided equally between Suhur and Iftar. In a recent review of the literature,9 fasting
during Ramadan was found to be well tolerated in T2DM patients who were compli-
ant with their diet and drug intake. This study also found that in patients with TIDM
who wish to fast, it is important to have good glycemic control and that these patients
might achieve better control with fast absorption insulin. It also suggested that pa-
tients self-monitor blood glucose levels several times a day.
In the present study, each patient's condition was well controlled during and after
the Ramadan fast, with mean HbA1c concentrations of 7.0% and 7.4%, respectively.
The lack of change in HbA1c concentrations might have been due to the short time
frame (28 days) of the Ramadan fast, which is a limitation of this case series and other
studies of fasting during Ramadan. The main outcomes of this study were the lack of
episodes of ketoacidosis or severe symptomatic daytime or nocturnal hypoglycemia
requiring treatment.
Insulin adjustment is not the only factor to consider in maintaining glycemic con-
trol. Physicians playa crucial role in advising patients and their families on how to
carry out the fasting ritual without causing clinical complications. Nutritional coun-
seling before, during, and after fasting is important in assisting adolescents and adults
in maintaining proper growth and nutrition.
This report provides insight into appropriate adjustment of basal insulin dosing
in patients with TIDM receiving insulin pump therapy who desire to fast during
Ramadan. Based on our clinical experience, we recommend decreasing the basal
insulin requirement by 5.5% to 25.0% provided they are under close supervision by
their endocrine team (endocrinologist, registered nutritionist, and diabetes educa-
tional nurse). Multicenter, controlled trials are needed to further research this issue
and provide useful clinical guidelines.
CONCLUSIONS
In this case series, adolescent and adult patients with TIDM who wished to fast
during Ramadan were able to do so because, based on blood glucose concentrations
on self-monitoring, basal insulin requirements decreased by 5.5 % to 25.0% or re-
mained the same. Blood glucose concentrations were relatively well maintained in
these patients using self-monitoring by finger stick testing and weekly follow-up with
their physicians.
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